Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01179048




Registration number
NCT01179048
Ethics application status
Date submitted
6/08/2010
Date registered
10/08/2010
Date last updated
17/07/2019

Titles & IDs
Public title
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Scientific title
A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
Secondary ID [1] 0 0
2009-012201-19
Secondary ID [2] 0 0
EX2211-3748
Universal Trial Number (UTN)
Trial acronym
LEADER®
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes 0 0
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - liraglutide
Treatment: Drugs - placebo

Experimental: Liraglutide -

Placebo comparator: Placebo -


Treatment: Drugs: liraglutide
Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment

Treatment: Drugs: placebo
Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)
Timepoint [1] 0 0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Secondary outcome [1] 0 0
Time From Rand. to First Occurrence of an Expanded Composite Cardiovascular Outcome Defined as Either Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, Revascularisation, Hospitalisation for Unstable Angina or for Heart Failure.
Timepoint [1] 0 0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Secondary outcome [2] 0 0
Time From Randomisation to All Cause Death
Timepoint [2] 0 0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Secondary outcome [3] 0 0
Time From Randomisation to Each Individual Component of the Expanded Composite Cardiovascular Outcome
Timepoint [3] 0 0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Secondary outcome [4] 0 0
Time From Randomisation to First Occurrence of a Composite Microvascular Outcome
Timepoint [4] 0 0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Secondary outcome [5] 0 0
Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.
Timepoint [5] 0 0
from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Eligibility
Key inclusion criteria
- Type 2 diabetes - Age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure OR age min. 60 years at screening and other specified risk factors of cardiovascular disease - HbA1c: 7.0% or above - Anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s)
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Type 1 diabetes - Use of a glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Short-term use of other insulin during this period in connection with intercurrent illness is allowed, at Investigator's discretion

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
Novo Nordisk Investigational Site - Blacktown
Recruitment hospital [2] 0 0
Novo Nordisk Investigational Site - Douglas
Recruitment hospital [3] 0 0
Novo Nordisk Investigational Site - Herston
Recruitment hospital [4] 0 0
Novo Nordisk Investigational Site - Meadowbrook
Recruitment hospital [5] 0 0
Novo Nordisk Investigational Site - Keswick
Recruitment hospital [6] 0 0
Novo Nordisk Investigational Site - Oaklands Park
Recruitment hospital [7] 0 0
Novo Nordisk Investigational Site - Hobart
Recruitment hospital [8] 0 0
Novo Nordisk Investigational Site - Box Hill
Recruitment hospital [9] 0 0
Novo Nordisk Investigational Site - Fitzroy
Recruitment hospital [10] 0 0
Novo Nordisk Investigational Site - Fremantle
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
4814 - Douglas
Recruitment postcode(s) [3] 0 0
4029 - Herston
Recruitment postcode(s) [4] 0 0
4131 - Meadowbrook
Recruitment postcode(s) [5] 0 0
5035 - Keswick
Recruitment postcode(s) [6] 0 0
5046 - Oaklands Park
Recruitment postcode(s) [7] 0 0
7000 - Hobart
Recruitment postcode(s) [8] 0 0
3128 - Box Hill
Recruitment postcode(s) [9] 0 0
3065 - Fitzroy
Recruitment postcode(s) [10] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Delaware
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
Montana
Country [19] 0 0
United States of America
State/province [19] 0 0
Nebraska
Country [20] 0 0
United States of America
State/province [20] 0 0
New Hampshire
Country [21] 0 0
United States of America
State/province [21] 0 0
New Jersey
Country [22] 0 0
United States of America
State/province [22] 0 0
New York
Country [23] 0 0
United States of America
State/province [23] 0 0
North Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Utah
Country [31] 0 0
United States of America
State/province [31] 0 0
Vermont
Country [32] 0 0
United States of America
State/province [32] 0 0
Washington
Country [33] 0 0
United States of America
State/province [33] 0 0
Wisconsin
Country [34] 0 0
Austria
State/province [34] 0 0
Graz
Country [35] 0 0
Austria
State/province [35] 0 0
Wien
Country [36] 0 0
Belgium
State/province [36] 0 0
Edegem
Country [37] 0 0
Belgium
State/province [37] 0 0
Gent
Country [38] 0 0
Belgium
State/province [38] 0 0
Leuven
Country [39] 0 0
Belgium
State/province [39] 0 0
Liège
Country [40] 0 0
Brazil
State/province [40] 0 0
Ceara
Country [41] 0 0
Brazil
State/province [41] 0 0
Goias
Country [42] 0 0
Brazil
State/province [42] 0 0
Parana
Country [43] 0 0
Brazil
State/province [43] 0 0
Para
Country [44] 0 0
Brazil
State/province [44] 0 0
Rio Grande Do Sul
Country [45] 0 0
Brazil
State/province [45] 0 0
Sao Paulo
Country [46] 0 0
Brazil
State/province [46] 0 0
Aracajú
Country [47] 0 0
Brazil
State/province [47] 0 0
Belo Horizonte
Country [48] 0 0
Brazil
State/province [48] 0 0
Campinas
Country [49] 0 0
Brazil
State/province [49] 0 0
Curitiba
Country [50] 0 0
Brazil
State/province [50] 0 0
Fortaleza
Country [51] 0 0
Brazil
State/province [51] 0 0
Goiânia
Country [52] 0 0
Brazil
State/province [52] 0 0
Joinville
Country [53] 0 0
Brazil
State/province [53] 0 0
Marília
Country [54] 0 0
Brazil
State/province [54] 0 0
Porto Alegre
Country [55] 0 0
Brazil
State/province [55] 0 0
Recife
Country [56] 0 0
Brazil
State/province [56] 0 0
Rio de Janeiro
Country [57] 0 0
Brazil
State/province [57] 0 0
Santos
Country [58] 0 0
Brazil
State/province [58] 0 0
São Paulo
Country [59] 0 0
Canada
State/province [59] 0 0
Alberta
Country [60] 0 0
Canada
State/province [60] 0 0
British Columbia
Country [61] 0 0
Canada
State/province [61] 0 0
Manitoba
Country [62] 0 0
Canada
State/province [62] 0 0
Newfoundland and Labrador
Country [63] 0 0
Canada
State/province [63] 0 0
Nova Scotia
Country [64] 0 0
Canada
State/province [64] 0 0
Ontario
Country [65] 0 0
Canada
State/province [65] 0 0
Quebec
Country [66] 0 0
China
State/province [66] 0 0
Beijing
Country [67] 0 0
China
State/province [67] 0 0
Fujian
Country [68] 0 0
China
State/province [68] 0 0
Guangdong
Country [69] 0 0
China
State/province [69] 0 0
Jiangsu
Country [70] 0 0
China
State/province [70] 0 0
Shandong
Country [71] 0 0
China
State/province [71] 0 0
Shanghai
Country [72] 0 0
Czechia
State/province [72] 0 0
Plzen
Country [73] 0 0
Czechia
State/province [73] 0 0
Praha
Country [74] 0 0
Denmark
State/province [74] 0 0
Aalborg
Country [75] 0 0
Denmark
State/province [75] 0 0
Esbjerg
Country [76] 0 0
Denmark
State/province [76] 0 0
Gentofte
Country [77] 0 0
Denmark
State/province [77] 0 0
Hvidovre
Country [78] 0 0
Denmark
State/province [78] 0 0
Odense
Country [79] 0 0
Denmark
State/province [79] 0 0
Århus C
Country [80] 0 0
Finland
State/province [80] 0 0
Kuopio
Country [81] 0 0
Finland
State/province [81] 0 0
Lahti
Country [82] 0 0
Finland
State/province [82] 0 0
Oulu
Country [83] 0 0
Finland
State/province [83] 0 0
Tampere
Country [84] 0 0
Finland
State/province [84] 0 0
Vantaa
Country [85] 0 0
France
State/province [85] 0 0
Corbeil Essonnes
Country [86] 0 0
France
State/province [86] 0 0
Jarny
Country [87] 0 0
France
State/province [87] 0 0
Nimes
Country [88] 0 0
France
State/province [88] 0 0
Paris
Country [89] 0 0
Germany
State/province [89] 0 0
Angermünde/OT Wolletz
Country [90] 0 0
Germany
State/province [90] 0 0
Aschaffenburg
Country [91] 0 0
Germany
State/province [91] 0 0
Berlin
Country [92] 0 0
Germany
State/province [92] 0 0
Dillingen
Country [93] 0 0
Germany
State/province [93] 0 0
Dresden
Country [94] 0 0
Germany
State/province [94] 0 0
Elsterwerda
Country [95] 0 0
Germany
State/province [95] 0 0
Essen
Country [96] 0 0
Germany
State/province [96] 0 0
Falkensee
Country [97] 0 0
Germany
State/province [97] 0 0
Gifhorn
Country [98] 0 0
Germany
State/province [98] 0 0
Hamburg
Country [99] 0 0
Germany
State/province [99] 0 0
Karlsbad
Country [100] 0 0
Germany
State/province [100] 0 0
Leipzig
Country [101] 0 0
Germany
State/province [101] 0 0
Ludwigshafen
Country [102] 0 0
Germany
State/province [102] 0 0
Mannheim
Country [103] 0 0
Germany
State/province [103] 0 0
München
Country [104] 0 0
Germany
State/province [104] 0 0
Oldenburg
Country [105] 0 0
Germany
State/province [105] 0 0
Saint Ingbert-Oberwürzbach
Country [106] 0 0
Germany
State/province [106] 0 0
Schkeuditz
Country [107] 0 0
Germany
State/province [107] 0 0
Schweinfurt
Country [108] 0 0
Germany
State/province [108] 0 0
Ulm
Country [109] 0 0
Germany
State/province [109] 0 0
Villingen-Schwenningen
Country [110] 0 0
Germany
State/province [110] 0 0
Wangen
Country [111] 0 0
Greece
State/province [111] 0 0
Athens
Country [112] 0 0
Greece
State/province [112] 0 0
Crete
Country [113] 0 0
Greece
State/province [113] 0 0
Thessaloniki
Country [114] 0 0
India
State/province [114] 0 0
Andhra Pradesh
Country [115] 0 0
India
State/province [115] 0 0
Assam
Country [116] 0 0
India
State/province [116] 0 0
Haryana
Country [117] 0 0
India
State/province [117] 0 0
Karnataka
Country [118] 0 0
India
State/province [118] 0 0
Kerala
Country [119] 0 0
India
State/province [119] 0 0
Madhya Pradesh
Country [120] 0 0
India
State/province [120] 0 0
Maharashtra
Country [121] 0 0
India
State/province [121] 0 0
Punjab
Country [122] 0 0
India
State/province [122] 0 0
Tamil Nadu
Country [123] 0 0
India
State/province [123] 0 0
West Bengal
Country [124] 0 0
India
State/province [124] 0 0
Thriruvananthapuram
Country [125] 0 0
Ireland
State/province [125] 0 0
Dublin 9
Country [126] 0 0
Ireland
State/province [126] 0 0
Dublin
Country [127] 0 0
Israel
State/province [127] 0 0
Haifa
Country [128] 0 0
Israel
State/province [128] 0 0
Jerusalem
Country [129] 0 0
Israel
State/province [129] 0 0
Petah-Tikva
Country [130] 0 0
Israel
State/province [130] 0 0
Tel Hashomer
Country [131] 0 0
Italy
State/province [131] 0 0
Bologna
Country [132] 0 0
Italy
State/province [132] 0 0
Catanzaro
Country [133] 0 0
Italy
State/province [133] 0 0
Chieti
Country [134] 0 0
Italy
State/province [134] 0 0
Firenze
Country [135] 0 0
Italy
State/province [135] 0 0
Latina
Country [136] 0 0
Italy
State/province [136] 0 0
Lucca
Country [137] 0 0
Italy
State/province [137] 0 0
Milano
Country [138] 0 0
Italy
State/province [138] 0 0
Padova
Country [139] 0 0
Italy
State/province [139] 0 0
Palermo
Country [140] 0 0
Italy
State/province [140] 0 0
Roma
Country [141] 0 0
Korea, Republic of
State/province [141] 0 0
Goyang
Country [142] 0 0
Korea, Republic of
State/province [142] 0 0
Seongnam-si
Country [143] 0 0
Korea, Republic of
State/province [143] 0 0
Seoul
Country [144] 0 0
Mexico
State/province [144] 0 0
Baja California Norte
Country [145] 0 0
Mexico
State/province [145] 0 0
Jalisco
Country [146] 0 0
Mexico
State/province [146] 0 0
Aguascalientes
Country [147] 0 0
Mexico
State/province [147] 0 0
Durango
Country [148] 0 0
Mexico
State/province [148] 0 0
Monterrey
Country [149] 0 0
Mexico
State/province [149] 0 0
San Luis Potosi
Country [150] 0 0
Netherlands
State/province [150] 0 0
Amsterdam
Country [151] 0 0
Netherlands
State/province [151] 0 0
Eindhoven
Country [152] 0 0
Netherlands
State/province [152] 0 0
Etten-Leur
Country [153] 0 0
Netherlands
State/province [153] 0 0
Goes
Country [154] 0 0
Netherlands
State/province [154] 0 0
Groningen
Country [155] 0 0
Netherlands
State/province [155] 0 0
Hoogeveen
Country [156] 0 0
Netherlands
State/province [156] 0 0
Maastricht
Country [157] 0 0
Netherlands
State/province [157] 0 0
Nijmegen
Country [158] 0 0
Netherlands
State/province [158] 0 0
Utrecht
Country [159] 0 0
Norway
State/province [159] 0 0
Oslo
Country [160] 0 0
Norway
State/province [160] 0 0
Stavanger
Country [161] 0 0
Norway
State/province [161] 0 0
Trondheim
Country [162] 0 0
Norway
State/province [162] 0 0
Tønsberg
Country [163] 0 0
Poland
State/province [163] 0 0
Bialystok
Country [164] 0 0
Poland
State/province [164] 0 0
Bydgoszcz
Country [165] 0 0
Poland
State/province [165] 0 0
Katowice
Country [166] 0 0
Poland
State/province [166] 0 0
Krakow
Country [167] 0 0
Poland
State/province [167] 0 0
Lodz
Country [168] 0 0
Poland
State/province [168] 0 0
Poznan
Country [169] 0 0
Poland
State/province [169] 0 0
Pulawy
Country [170] 0 0
Poland
State/province [170] 0 0
Ruda Slaska
Country [171] 0 0
Poland
State/province [171] 0 0
Warszawa
Country [172] 0 0
Poland
State/province [172] 0 0
Wroclaw
Country [173] 0 0
Puerto Rico
State/province [173] 0 0
Bayamon
Country [174] 0 0
Puerto Rico
State/province [174] 0 0
Caguas
Country [175] 0 0
Romania
State/province [175] 0 0
Dolj
Country [176] 0 0
Romania
State/province [176] 0 0
Mures
Country [177] 0 0
Romania
State/province [177] 0 0
Timis
Country [178] 0 0
Romania
State/province [178] 0 0
Bacau
Country [179] 0 0
Romania
State/province [179] 0 0
Bucharest
Country [180] 0 0
Romania
State/province [180] 0 0
Constanta
Country [181] 0 0
Romania
State/province [181] 0 0
Deva
Country [182] 0 0
Romania
State/province [182] 0 0
Iasi
Country [183] 0 0
Romania
State/province [183] 0 0
Satu Mare
Country [184] 0 0
Romania
State/province [184] 0 0
Sibiu
Country [185] 0 0
Russian Federation
State/province [185] 0 0
Arkhangelsk
Country [186] 0 0
Russian Federation
State/province [186] 0 0
Barnaul
Country [187] 0 0
Russian Federation
State/province [187] 0 0
Kazan
Country [188] 0 0
Russian Federation
State/province [188] 0 0
Moscow
Country [189] 0 0
Russian Federation
State/province [189] 0 0
Nizhniy Novgorod
Country [190] 0 0
Russian Federation
State/province [190] 0 0
Penza
Country [191] 0 0
Russian Federation
State/province [191] 0 0
Saratov
Country [192] 0 0
Russian Federation
State/province [192] 0 0
Smolensk
Country [193] 0 0
Russian Federation
State/province [193] 0 0
Tumen
Country [194] 0 0
Russian Federation
State/province [194] 0 0
Yaroslavl
Country [195] 0 0
Serbia
State/province [195] 0 0
Belgrade
Country [196] 0 0
South Africa
State/province [196] 0 0
Free State
Country [197] 0 0
South Africa
State/province [197] 0 0
Gauteng
Country [198] 0 0
South Africa
State/province [198] 0 0
KwaZulu-Natal
Country [199] 0 0
South Africa
State/province [199] 0 0
Western Cape
Country [200] 0 0
South Africa
State/province [200] 0 0
Alberton
Country [201] 0 0
South Africa
State/province [201] 0 0
Cape Town
Country [202] 0 0
Spain
State/province [202] 0 0
Almería
Country [203] 0 0
Spain
State/province [203] 0 0
Barcelona
Country [204] 0 0
Spain
State/province [204] 0 0
La Coruña
Country [205] 0 0
Spain
State/province [205] 0 0
Madrid
Country [206] 0 0
Spain
State/province [206] 0 0
Mora De Ebre
Country [207] 0 0
Spain
State/province [207] 0 0
Mostoles - Madrid -
Country [208] 0 0
Spain
State/province [208] 0 0
Palma de Mallorca
Country [209] 0 0
Spain
State/province [209] 0 0
Pozuelo de Alarcon
Country [210] 0 0
Spain
State/province [210] 0 0
Sevilla
Country [211] 0 0
Spain
State/province [211] 0 0
Valladolid
Country [212] 0 0
Sweden
State/province [212] 0 0
Göteborg
Country [213] 0 0
Sweden
State/province [213] 0 0
Malmö
Country [214] 0 0
Sweden
State/province [214] 0 0
Stockholm
Country [215] 0 0
Sweden
State/province [215] 0 0
Örebro
Country [216] 0 0
Taiwan
State/province [216] 0 0
Changhua City
Country [217] 0 0
Taiwan
State/province [217] 0 0
Kaoshiung
Country [218] 0 0
Taiwan
State/province [218] 0 0
Tainan city
Country [219] 0 0
Taiwan
State/province [219] 0 0
Taoyuan
Country [220] 0 0
Turkey
State/province [220] 0 0
Ankara
Country [221] 0 0
Turkey
State/province [221] 0 0
Antalya
Country [222] 0 0
Turkey
State/province [222] 0 0
Bursa
Country [223] 0 0
Turkey
State/province [223] 0 0
Gaziantep
Country [224] 0 0
Turkey
State/province [224] 0 0
Istanbul
Country [225] 0 0
Turkey
State/province [225] 0 0
Izmir
Country [226] 0 0
Turkey
State/province [226] 0 0
Kayseri
Country [227] 0 0
United Arab Emirates
State/province [227] 0 0
Dubai
Country [228] 0 0
United Kingdom
State/province [228] 0 0
Aberdeen
Country [229] 0 0
United Kingdom
State/province [229] 0 0
Birmingham
Country [230] 0 0
United Kingdom
State/province [230] 0 0
Bristol
Country [231] 0 0
United Kingdom
State/province [231] 0 0
Coventry
Country [232] 0 0
United Kingdom
State/province [232] 0 0
Devon
Country [233] 0 0
United Kingdom
State/province [233] 0 0
Dundee
Country [234] 0 0
United Kingdom
State/province [234] 0 0
Edinburgh
Country [235] 0 0
United Kingdom
State/province [235] 0 0
Glasgow
Country [236] 0 0
United Kingdom
State/province [236] 0 0
Guildford
Country [237] 0 0
United Kingdom
State/province [237] 0 0
Hull
Country [238] 0 0
United Kingdom
State/province [238] 0 0
Livington
Country [239] 0 0
United Kingdom
State/province [239] 0 0
London
Country [240] 0 0
United Kingdom
State/province [240] 0 0
Manchester
Country [241] 0 0
United Kingdom
State/province [241] 0 0
Norwich
Country [242] 0 0
United Kingdom
State/province [242] 0 0
Nuneaton
Country [243] 0 0
United Kingdom
State/province [243] 0 0
Plymouth
Country [244] 0 0
United Kingdom
State/province [244] 0 0
St Helens
Country [245] 0 0
United Kingdom
State/province [245] 0 0
Swansea
Country [246] 0 0
United Kingdom
State/province [246] 0 0
Torquay
Country [247] 0 0
United Kingdom
State/province [247] 0 0
West Midlands

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novo Nordisk A/S
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
Trial website
https://clinicaltrials.gov/study/NCT01179048
Trial related presentations / publications
Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2019 Jul;21(7):1745-1751. doi: 10.1111/dom.13698. Epub 2019 Apr 2.
Hinton W, Feher M, Munro N, Walker M, de Lusignan S. Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. Diabetes Obes Metab. 2019 Jul;21(7):1661-1667. doi: 10.1111/dom.13710. Epub 2019 Apr 11.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
Petrie JR, Marso SP, Bain SC, Franek E, Jacob S, Masmiquel L, Leiter LA, Haluzik M, Satman I, Omar M, Shestakova M, Van Gaal L, Mann JF, Baeres FM, Zinman B, Poulter NR; LEADER investigators. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. J Hypertens. 2016 Jun;34(6):1140-50. doi: 10.1097/HJH.0000000000000890.
Masmiquel L, Leiter LA, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S, van Gaal L, Baeres FM, Marso SP, Eriksson M; LEADER investigators. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol. 2016 Feb 10;15:29. doi: 10.1186/s12933-016-0341-5.
Satman I, R Rea R, Eriksson M, Mosenzon O, Pratley R, M Baeres F, D Orsted D, F Mann J; LEADER Trial Investigators. LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. J Diabetes Complications. 2016 Nov-Dec;30(8):1631-1639. doi: 10.1016/j.jdiacomp.2016.06.001. Epub 2016 Jun 3.
Rutten GE, Tack CJ, Pieber TR, Comlekci A, Orsted DD, Baeres FM, Marso SP, Buse JB; LEADER Investigators. LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. Diabetol Metab Syndr. 2016 Jun 2;8:37. doi: 10.1186/s13098-016-0153-5. eCollection 2016.
Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013 Nov;166(5):823-30.e5. doi: 10.1016/j.ahj.2013.07.012. Epub 2013 Oct 2.
Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB; LEADER Trial investigators. LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas. 2014 Nov;43(8):1223-31. doi: 10.1097/MPA.0000000000000229.
Daniels GH, Hegedus L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann JF, Derving Karsbol J, Moses AC, Buse JB, Tuttle RM; LEADER Trial Investigators. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. Diabetes Obes Metab. 2015 May;17(5):477-86. doi: 10.1111/dom.12444. Epub 2015 Feb 23.
Steinberg WM, Buse JB, Ghorbani MLM, Orsted DD, Nauck MA; LEADER Steering Committee; LEADER Trial Investigators. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care. 2017 Jul;40(7):966-972. doi: 10.2337/dc16-2747. Epub 2017 May 5.
Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornoe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.
Hegedus L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbol JD, Daniels GH; LEADER Publication Committee on behalf of the LEADER Trial Investigators. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018 Mar;41(3):620-622. doi: 10.2337/dc17-1956. Epub 2017 Dec 26.
Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). Am J Cardiol. 2018 Jun 15;121(12):1467-1470. doi: 10.1016/j.amjcard.2018.02.030. Epub 2018 Mar 15.
Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. Circulation. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. No abstract available.
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018 Aug;41(8):1663-1671. doi: 10.2337/dc17-1825. Epub 2018 Jun 13.
Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care. 2018 Aug;41(8):1783-1791. doi: 10.2337/dc17-2677. Epub 2018 Jun 14.
Nauck MA, Tornoe K, Rasmussen S, Treppendahl MB, Marso SP; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diab Vasc Dis Res. 2018 Sep;15(5):465-468. doi: 10.1177/1479164118783935. Epub 2018 Jun 27.
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornoe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care. 2018 Oct;41(10):2229-2235. doi: 10.2337/dc18-1094. Epub 2018 Aug 2.
Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Marso S, Nauck M, Zinman B, Bosch-Traberg H, Rasmussen S, Michelsen MM, Bhatt DL. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation. 2018 Oct 9;138(15):1605-1607. doi: 10.1161/CIRCULATIONAHA.118.036862. No abstract available.
Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 2018 Dec 18;138(25):2908-2918. doi: 10.1161/CIRCULATIONAHA.118.036418.
Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Orsted DD, Monk Fries T, Rasmussen S, Marso SP. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.
Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A; LEADER Publication Committee for the LEADER Trial Investigators. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obes Metab. 2019 Mar;21(3):525-532. doi: 10.1111/dom.13547. Epub 2018 Oct 25.
Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Orsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Liraglutide and Glycaemic Outcomes in the LEADER Trial. Diabetes Ther. 2018 Dec;9(6):2383-2392. doi: 10.1007/s13300-018-0524-z. Epub 2018 Nov 3.
Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Rea RR, Kerr Saraiva JF, Rasmussen S, Tornoe K, von Scholten BJ, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Ann Intern Med. 2019 Mar 19;170(6):423-426. doi: 10.7326/M18-1569. Epub 2018 Dec 4. No abstract available.
Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, Sejersten Ripa M, Bonaca MP. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022 Jul;24(7):1288-1299. doi: 10.1111/dom.14700. Epub 2022 Apr 11.
Heller SR, Geybels MS, Iqbal A, Liu L, Wagner L, Chow E. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia. 2022 Jan;65(1):55-64. doi: 10.1007/s00125-021-05556-7. Epub 2021 Oct 26.
Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Rossing P; LEADER Trial Investigators. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care. 2021 Apr;44(4):1020-1026. doi: 10.2337/dc20-1622. Epub 2021 Jan 27.
Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, Monk Fries T, Pratley RE, Rasmussen S, Vrazic H, Zinman B, Buse JB. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Dec;22(12):2487-2492. doi: 10.1111/dom.14160. Epub 2020 Sep 4.
Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 Sep;43(9):e108-e110. doi: 10.2337/dc20-0437. Epub 2020 Jul 9. No abstract available.
Verma S, Bain SC, Honore JB, F E Mann J, A Nauck M, E Pratley R, Rasmussen S, Sejersten Ripa M, Zinman B, Buse JB. Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2020 Nov;22(11):2193-2198. doi: 10.1111/dom.14140. Epub 2020 Aug 12.
Leiter LA, Bain SC, Bhatt DL, Buse JB, Mazer CD, Pratley RE, Rasmussen S, Ripa MS, Vrazic H, Verma S. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Sep;22(9):1690-1695. doi: 10.1111/dom.14079. Epub 2020 Jun 3.
Buse JB, Bain SC, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Pratley RE, Linder M, Monk Fries T, Orsted DD, Zinman B; LEADER Trial Investigators. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care. 2020 Jul;43(7):1546-1552. doi: 10.2337/dc19-2251. Epub 2020 May 4.
Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, Poulter NR, Pratley RE, Thomsen AB, Buse JB; LEADER Trial Investigators. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. J Am Coll Cardiol. 2020 Mar 17;75(10):1128-1141. doi: 10.1016/j.jacc.2019.12.063.
Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O; LEADER Trial Investigators. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clin J Am Soc Nephrol. 2020 Apr 7;15(4):465-473. doi: 10.2215/CJN.11881019. Epub 2020 Mar 4.
Nauck MA, Kreiner E, Rasmussen S, Saevereid HA, Buse JB; LEADER Trial Investigators. Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920. Diabetes Care. 2020 Feb;43(2):e30-e31. doi: 10.2337/dci19-0067. No abstract available.
Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Orsted DD, Nauck MA. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 Dec 1;4(12):1214-1220. doi: 10.1001/jamacardio.2019.3080.
Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019 Oct;42(10):1912-1920. doi: 10.2337/dc19-0415. Epub 2019 Aug 9.
Tack CJ, Jacob S, Desouza C, Bain SC, Buse JB, Nauck MA, Petrie JR, Poulter NR, Pratley RE, Stegmann HVBK, Bosch-Traberg H, Startseva E, Zinman B; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes Obes Metab. 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7.
Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018 Apr;24(8 Suppl):S146-S155.
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Registry (GCR, 1452)
Address 0 0
Novo Nordisk A/S
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01179048